BioAge Labs (BIOA) Stock Forecast: StockMap's 2-Week Call
BIOA stock forecast: StockMap's model leans Underperform on BioAge Labs for the two weeks after the Nov 19 close, toward BIOA trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on BIOA since Aug 21; by chance, a call on the same dates was right 59% of the time.
BioAge Labs last closed at $4.71, -1.26% on the session.
Against the IVW growth benchmark the position is +1.07% over the forecast window.
BioAge Labs' market cap is $216.46M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).
Where BIOA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
48 daily calls for BIOA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks BioAge Labs in the 23rd percentile on return on equity, where 100 is best.
BioAge Labs is classified under Health Care / Pharmaceuticals.
StockMap tracks BioAge Labs as the 90th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite BioAge Labs ranks 113th of 153 in the group, against a group median of -0.36.